ArticleMicrobial biotechnology2025
Broad-Spectrum Antimicrobial and Antibiofilm Activities of Halogenated Anilines Against Uropathogenic Escherichia coli and ESKAPE Pathogens.
Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Uropathogenic Escherichia coli (UPEC) is one of the leading causes of nosocomial infections and urinary tract infections (UTIs), capable of inducing a spectrum of conditions ranging from acute bladder cystitis to chronic pyelonephritis. The virulence arsenal of UPEC includes factors, such as curli fimbriae, hemolysin, motility elements and metallophores. Moreover, UPEC can form biofilm-like communities and quiescent intracellular reservoirs within host tissues, contributing to recurrent and persistent infections. This study investigates the antibiofilm and antimicrobial activities of two halogen-substituted aniline derivatives, 4-bromo-3-chloroaniline (4B3CA) and 3,5-dibromoaniline (3,5-DBA), against UPEC. The compounds demonstrated minimum inhibitory concentrations (MICs) of 200 μg/mL for 4B3CA and 100 μg/mL for 3,5-DBA, with both exhibiting a biofilm inhibition IC50 value of 10 μg/mL. Additionally, these derivatives showed antibiofilm activity against ESKAPE pathogens. Treatment with 4B3CA and 3,5-DBA led to significant downregulation of UPEC virulence- and biofilm-related genes, including those involved in curli production, fimbrial adhesion, motility, iron acquisition, quiescent colony formation, and stress response. Interestingly, a mild upregulation of hlyA, csrA and uvrY was noted, alongside a marked downregulation of the adenylate cyclase genes cyaA and crp. These findings suggest that inhibition of adenylate cyclase activity may be a primary mode of action, leading to both antimicrobial and antibiofilm effects. The presence of halogen atoms in these compounds appears to enhance their binding affinity to adenylate cyclase through stabilising halogen bond interactions. Furthermore, 3D-QSAR analysis indicates that electrostatic favourability at the third and fourth positions of the aniline ring is critical for bioactivity. Finally, in silico ADMET profiling and cytotoxicity assessments using Caenorhabditis elegans suggest that these aniline derivatives hold promise as therapeutic candidates, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.